The beta2-agonist salbutamol affects the expression of phospholamban and both isoforms of SERCA in canine skeletal muscle and blocks changes in these induced by neuromuscular stimulation.
Chronic administration of salbutamol induced expression of hybrid fibers in canine skeletal muscles. Fast-twitch fibers expressed SERCA2a (the slow-twitch isoform of sarcoplasmic reticulum Ca2+-ATPase) and slow-twitch fibers expressed SERCA1 (the fast-twitch isoform of the Ca2+-ATPase). The proportion of fibers that became hybrid increased from a small percentage in the control muscles to 30% in the predominantly fast-twitch latissimus dorsi and to 45% in the predominantly slow-twitch vastus intermedius. In contrast to this response by the SERCA genes the phospholamban gene response was muscle specific. The fraction of fibers that expressed phospholamban decreased slightly in the latissimus dorsi while increasing moderately in the vastus intermedius. The effects of chronic neurostimulation of the latissimus dorsi on SERCA1, SERCA2a and phospholamban levels were mostly blocked by salbutamol. While 100% of fibers from neurostimulated muscles expressed phospholamban, only 51% of the fibers from the neurostimulated and salbutamol-treated muscles expressed it. In the neurostimulated muscle, very few muscle fibers expressed SERCA1a while 61% of the fibers that received salbutamol expressed it, albeit as hybrid fibers. The levels of SERCA2a in response to these interventions were just the opposite. In the neurostimulated muscle 37.5% of fibers were hybrid and 62.5% expressed SERCA2a only. With co-administration of neurostimulation and salbutamol, 61.3% of fibers were hybrid and 38.7% expressed SERCA2a only.
Zhang
K M
KM
Department of Physiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA.
Hu
P
P
Wang
S W
SW
Wright
L D
LD
Wechsler
A S
AS
Spratt
J A
JA
Briggs
F N
FN
D058647:Adrenergic alpha-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000494:pharmacology*; D000818:Animals; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D000252:Calcium-Transporting ATPases / Q000096:biosynthesis*; D004285:Dogs; D004558:Electric Stimulation; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000096:biosynthesis*; D018656:Muscle Fibers, Fast-Twitch / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000201:enzymology*; D000099211:Phospholamban
D058647:Adrenergic alpha-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000420:Albuterol; D002135:Calcium-Binding Proteins; D000252:Calcium-Transporting ATPases; D007527:Isoenzymes; D000099211:Phospholamban